Immune optimization peptides
Immune-optimization peptides modulate distinct arms of the immune system: thymosin alpha-1 activates dendritic cells and enhances T-cell function, ARA-290 reduces inflammation through innate-repair receptor binding (without erythropoietin's red-blood-cell effects), and KPV downregulates NF-kB signaling and pro-inflammatory cytokines. PeptideRx (rxpepsdirect.com) prescribes the major immune peptides plus higher-strength formulations for active-illness loading protocols.
- Thymosin alpha-1 has the strongest evidence base of any compounded immune peptide.
- Thymosin alpha-1 is approved internationally as Zadaxin for chronic hepatitis B.
- ARA-290 is studied for diabetic neuropathy and sarcoidosis-associated inflammation.
- KPV is one of the smallest known anti-inflammatory peptides and is studied for IBD adjunct use.
Thymosin Alpha-1
$80/15mgDual-listed immune peptide. Approved in 35+ countries for immune modulation and T-cell enhancement.
ARA-290
$80/30mgDual-listed innate repair receptor agonist for immune recovery and tissue protection.
KPV (in BPC Combos)
Via comboPotent anti-inflammatory tripeptide available in BPC-157 combination formulations.
Comparing immune optimization peptides
Immune peptides PeptideRx prescribes, with mechanism and protocol context.
| Thymosin Alpha-1 | Thymosin Alpha-1 (Immune) | ARA-290 | ARA-290 (Immune) | KPV Combo | |
|---|---|---|---|---|---|
| Mechanism | T-cell + dendritic activation | Higher concentration for loading | Innate repair receptor | Higher concentration for loading | NF-kB inhibitor |
| Best for | Maintenance immune support | Active illness loading | Neuropathic + inflammatory | Aggressive inflammation | Gut + chronic inflammation |
| Typical protocol | 1.6 mg twice weekly x 6-8 wk | 1.6 mg every other day x 1 wk, then 2x/wk | 1-4 mg daily x 4-8 wk | 1-4 mg, 3-7x/wk x 4-12 wk | Daily x 4-8 wk with breaks |
| International approval | Zadaxin (35+ countries) | Zadaxin (35+ countries) | Investigational | Investigational | Investigational |
| Starting price | Per provider | Per provider | Per provider | Per provider | Per provider |
What to expect on an immune peptide protocol
Acute illness protocols (thymosin alpha-1 immune loading) should start as early in the illness course as possible. Effects are gradual; most protocols run at least 4 to 8 weeks before assessment. Track symptom resolution and follow-up inflammatory or viral-load markers as available. Side-effect profiles are mild for all immune peptides at typical doses; injection-site reactions are the most common report.
Important Safety Information
- •Organ transplant recipients on immunosuppressants (flag)
- •Active autoimmune flare (flag for provider review)
Frequently asked questions about immune optimization peptides
- What is the strongest immune peptide?
- Thymosin alpha-1 has the strongest published evidence base of any compounded immune peptide. It is internationally approved as Zadaxin for chronic hepatitis B in 35+ countries and is used adjunctively in cancer-related immunosuppression. The mechanism involves dendritic-cell activation and enhanced T-cell function, which makes it particularly relevant for chronic infection and post-viral recovery protocols.
- Is thymosin alpha-1 FDA approved?
- Thymosin alpha-1 is not FDA-approved in the United States. It is approved internationally as Zadaxin in 35+ countries for chronic hepatitis B and as an adjunct in oncology. Compounding pharmacies in the U.S. dispense thymosin alpha-1 under Section 503A patient-specific prescriptions. Optimal Balance Pharmacy compounds and tests every batch through Eagle Analytical Services.
- How long should I run thymosin alpha-1 when sick?
- Acute illness protocols typically run 4 to 8 weeks total, sometimes with a higher-frequency loading schedule in the first week (every other day) followed by maintenance dosing (1.6 mg twice weekly). The thymosin alpha-1 immune formulation is a higher-concentration version designed for the loading phase. Maintenance protocols often run 1.6 mg once weekly for chronic-illness support.
- Does ARA-290 work for chronic inflammation?
- Phase II clinical trials showed ARA-290 reduced neuropathic pain scores in patients with sarcoidosis-associated small fiber neuropathy and improved corneal nerve fiber density in diabetic neuropathy. The peptide has not progressed to FDA approval but compounding-clinic use draws on the trial-evidence base for chronic neuropathic and inflammatory indications.
- Are immune peptides safe for long-term use?
- Thymosin alpha-1 has the longest safety record of the immune peptides, with international clinical use spanning decades. ARA-290 and KPV have shorter human safety records but no major safety signals at typical doses. Continuous long-term daily use is generally avoided in favor of episodic protocols (4 to 8 weeks at a time with breaks); your provider will set the cycle structure based on the indication.